{"url_path":"/sec/tars/8-k/2026-07-13/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/1819790/0001819790-26-000048-index.html","accession_number":"0001819790-26-000048","cik":"0001819790","ticker":"TARS","issuer_name":"Tarsus Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819790/0001819790-26-000048-index.html","primary_entity_key":"0001819790","primary_entity_name":"Tarsus Pharmaceuticals, Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nTarsus Pharmaceuticals, Inc.\n\nDate: July 13, 2026By:/s/ Bryan Wahl\n\nBryan Wahl\n\nGeneral Counsel and Secretary"}